盐酸吡格咧酮应用于2型糖尿病临床疗效评价

目的:评价口服降糖药盐酸吡格咧酮的临床疗效。方法:从本院收治的354例2型糖尿病患者临床资料中,选取其中使用磺脲类降糖药及与盐酸吡格咧酮联合治疗的86例,分成两组:A组(男24例,女26例),单独使用磺脲类药物治疗的病例;B组(男19例,女17例),使用磺脲类与盐酸吡格咧酮联合治疗的病例。对各组患者治疗前后体重、糖代谢、脂质代谢等指标的变化进行统计学分析。结果:B组和A组患者在治疗后血糖水平(PBG、FBG、HbAlc)均显著性地下降,但B组下降更快,两组的血糖水平在治疗后12周具显著差异(P<0.05);两组患者治疗前后胰岛素水平(PINS、FINS)的变化总体上是:A组增高(P<0.01),而B组降低(其中PINS降低具统计学意义,P<0.01,而FINS降低不具统计学意义),B组患者治疗后12周的餐后胰岛素水平(PINS)与A组患者治疗后12周的餐后胰岛素水平具显著差异(P<0.05);B组患者治疗后12周,总胆固醇(TC)、甘油三酯(TG)显著性地下降,但与A组的差异不具统计学意义;两组患者的HDL-c和BMI变化均无统计学意义。结论:盐酸吡格咧酮能改善胰岛素抵抗,纠正糖代谢及脂质代谢紊乱,不增加体重。

Evaluation of the Clinical Effects of Ptoglitazone Hydrochliride in Treatment of Type 2 Diabetes

Objective: To evaluate the clinical effects of pioglitazone hydrochliride in treatment of type 2 diabetes. Methods: 86 cases with 2 diabetic were enrolled, they were divided into two groups: Group A and Group B. in Group A the patients were treated only with sulphonylureas oral antihyperglycemic agents(men 24 and women 26); Group B the patients were treated with sulphonylureas oral antihyperglycemic agents and pioglitazone hydrochliride (men 19 and women 17) .A statistical analysis of the changes that took place in the patient's weight、lipid and sugar metablism before and after the treatment was performed. Results:The blood glucose lev-els(PBG、FBG、HbAlc)of the cases in Group B decreased more quickly than the cases in Group A after the treament,and the blood glucose levels between cases of the two groups were statistically different (P < 0.05); After 12 weeks' treatment,the changes of the insulin level was that Group A increased and Group B decreased (the PINS'decrease reached statistical significance (P <0.01) ,but the FINS' decrease didn' s reach statistical significance), and the difference of FINS between the two groups reached statistical significance ( P < 0.05). Although after 12 weeks' treatment, the TC and TG of the cases in Group B decreased obviously, they were not different from the cases in Group A in statistical significance.The changes of HDL-c and BMI in the two groups didn't show statistical significance. Conclusion: Pioglitazone hydrochliride can reduce insulin resistance in the cases with type 2 diabetes,and adjust the disorder of lipid and sugar metablism without the increase of weight.